CASE STUDY

Non-Invasive Stereotactic Radiosurgical Treatment of Non-Small cell Lung Cancer
### Clinical History

**Demographics**
- Sex: Male
- Age: 76 years
- Histology: Meningioma

**Referred by:** Neurosurgery

**Previous Treatment:** Previously resected

### Treatment Details

#### Gross Tumor Volume (GTV)
- Volume: 3.60 cm³

#### Imaging Technique
- CT

#### Rx Dose & Isodose
- 60 Gy to 75%

#### Conformity Index (PTV)
- 1.15

#### Number of beams
- 148 beams/fraction

#### Homogeneity Index
- 1.33

### Outcome and Follow-Up

Four months after CyberKnife® treatment CT imaging revealed an interval decrease in the size of the RUL lesion, which decreased in size to less than 1 cm in maximum dimension (0.9 cm x 0.8 cm x 0.9 cm). There were no noted acute complications. The patient remained asymptomatic with stable post-treatment PFTs.

### References

### Treatment Rationale
When possible, Stage I NSCLC is treated by primary surgical resection (lobectomy or segmentectomy). Conventional radiation therapy and chemotheraphy are reserved for patients who refuse surgery or who are deemed medically inoperable because of associated comorbidities. In recent years improved tumor control with relatively few complications has been achieved using high-dose, hypofractionated stereotactic radiotherapy delivery. This patient was a poor surgical candidate because of her depressed PFTs and her history of advanced COPD. Given the potential for sub-optimal outcomes of conventional radiation therapy, the inclusion of large volumes of normal lung tissue within the radiation field, and the patient’s prior history of external beam radiation to the right breast for treatment of her breast cancer in the past, CyberKnife® Radiosurgery using fiducial-free Xsight Lung Tumor Tracking was chosen to deliver focal, high-dose, hypofractionated radiation treatment that maximizes dose to this patient’s lung tumor and minimizes dose to surrounding normal tissue. Xsight Lung is a non-invasive method that allows the CyberKnife® System to track tumor motion throughout treatment without the need for implantation of metal fiducials in the lung tumor.

### Planning Process
The patient’s only preparation for treatment was a planning CT scan (with breath holding) to identify tumor target. No fiducials or implantation of any markers was required given the use of the Xsight® Lung technology. Following completion of imaging, the lesion was outlined on the scans resulting in a gross tumor volume of 3.60 cm³. A treatment plan was created to deliver 60 Gy in 3 fractions to the 75% isodose line 8-mm tumor margins to encompass microscopic extension (6 mm) and targeting uncertainties (2 mm), using the 20-mm and 30-mm collimators.

### Treatment Delivery
The patient underwent CyberKnife® treatment in an average of 57 minutes/fraction using 148 beams/fraction. The prescribed dose covered 100% of the tumor volume with a homogeneity index of 1.33 and a conformity index of 1.15 for the PTV. The patient tolerated the procedure well.

### Case History
A 72-year-old female smoker with a history of COPD presented with new onset of shortness of breath after waking less than 60 feet. No other symptoms were noted. Further evaluation by CT imaging demonstrated a new 1.8 cm x 1.6 cm x 1.7 cm lesion in the upper lobe of the right lung (RUL). Follow-up PET-CT imaging demonstrated increased SUV uptake of 5.2 within the lesion. No other regions of SUV uptake were noted. No increased SUV uptake within the nodes of the mediastinum was noted. Biopsy results demonstrated lesion to be consistent with NSCLC. Given the PET-CT and biopsy results, this patient was diagnosed with Stage 1a non-small cell lung cancer (Stage T1N0M0 NSCLC). The patient’s pre-treatment pulmonary function tests (PFTs) were below normal limits secondary to her history of smoking and advanced COPD. Her maximum oxygen consumption was 2.963 L/min (62% of predicted), normalized to body weight, her maximum oxygen consumption was 17.6 ML/KG/min (62% of predicted). The patient’s maximum minute ventilation at maximum exercise was 71% of predicted.

### Treatment Time
- Mean: 57 minutes/fraction
- Synchrony with Xsight Lung (No fiducials)

### Advantages
- The CyberKnife® System provides an excellent, completely non-invasive treatment option for patients with lung tumors who are poor surgical candidates because of associated medical conditions and are unable to tolerate any degree of invasiveness in the treatment of their cancer.

### Conclusion
The CyberKnife® System offers an excellent, completely non-invasive treatment option for patients with lung tumors who are poor surgical candidates because of associated medical conditions and are unable to tolerate any degree of invasiveness in the treatment of their cancer.